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A common haplotype spanning 250 kb in the cytokine gene cluster on chromosome 5q31 has recently been reported
to be strongly associated with Crohn disease (CD) in Canadian families. We have replicated this finding by both
the transmission-disequilibrium test (TDT) ( ) and in a case-control association study ( ) in a largePp .016 Pp .008
European cohort of patients with CD, although the increase in disease risk was small (odds ratio 1.49 for homo-
zygotes, 95% CI 1.11–2.0). No association was detected in families or individuals with ulcerative colitis (UC).
Stratification of offspring with CD in the TDT sample by mutation status in the CD susceptibility gene CARD15
showed that the association with the 5q31 risk haplotype was present only in offspring with at least one of the
knownCARD15 disease susceptibility alleles ( ). The 5q31 risk haplotype frequencywas 53.1% in unrelatedPp .044
individuals with CD who had one or two CARD15 mutations versus 43.7% in control subjects ( ) butPp .0001
was not significantly elevated in individuals with CD who had no CARD15 mutations (45.4%, ). Kaplan-Pp .41
Meier survival analysis of age at disease onset showed a significantly earlier onset in homozygotes for the 5q31
risk haplotype ( ). These findings suggest that genetic variants at the 5q31 (IBD5) locus may hasten thePp .0019
onset of Crohn disease and cooperate with CARD15 in disease causation.
Crohn disease (CD [MIM 266600]) and ulcerative colitis
(UC [MIM 191390]) are two forms of chronic inflam-
matory bowel disease (IBD) with distinct clinical features.
CD affects any part of the gastrointestinal tract, whereas
in UC the inflammation is confined to the colon and rec-
tum. Genetic linkage studies identified a susceptibility lo-
cus for CD on chromosome 16 (Hugot et al. 1996), and
subsequent positional cloning and candidate gene studies
revealed mutations in the NOD2 gene (now known as
CARD15) at this locus that were strongly associatedwith
CD (Hampe et al. 2001; Hugot et al. 2001; Ogura et al.
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2001). A genomewide search in Canadian families found
evidence of linkage to CD on chromosome 5q31 (Rioux
et al. 2000), and linkage disequilibrium (LD) mapping of
this locus detected association of a common haplotype in
the 5q31 cytokine gene cluster with CD (Rioux et al.
2001). This haplotype contained 11 SNPs that were in
almost complete LD with each other and were strongly
associated with disease. The recent report (Dahlman et
al. 2002) of a lack of confirmation of a published asso-
ciation between a genetic variant in the IL12B gene and
type 1 diabetes (Morahan et al. 2001) exemplifies the
importance of independent replication of such findings in
complex disorders. We therefore sought to replicate the
association of the 5q31 locus with CD in a large sample
of European patients. We also investigated whether this
association extends to UC, since common genes may con-
tribute to susceptibility to both of these IBD subpheno-
types (Watts and Satsangi 2002).
Two SNPs (C2063G and C2198G) that lie ∼67 kb
apart on the common disease-associated haplotype were
Reports 1019
Table 1
TDT and Case-Control Analyses for the C2063G SNP at 5q31
PHENOTYPE
VALUE FOR ANALYSIS
TDT Cases and Controls
NTDT
a Obsb Expc PTDT
d NCC
e CC CG GG Freq(G) PCC
f
CD 511 484 458.9 .016 684 190 327 167 48.3% .008
UC 320 249 263.3 .063 388 146 172 70 40.2% NSg
Control … … … … 701 231 334 136 43.2% …
a NTDT p number of affected offspring.
b Obs p observed number of transmissions of G allele to affected offspring.
c Exp p expected number of transmissions of G allele to affected offspring.
d PTDT p P value from TDT association of allele G.
e NCC p number of case and control subjects.
f PCCp P value from test for difference in frequency of allele G in cases and controls, assessed
with a x2 test.
g NS p not significant ( ).P 1 .05
Table 2
Case-Control Genotypes for the 5q31 and CARD15 Loci, with Disease Risk Estimated by Logistic Regression
CARD15
GENOTYPE
CONTROLS ( )aNp 676 CD CASES ( )aNp 943 5q31/CARD15 OR (95% CI)
CC CG GG Freq(G) CC CG GG Freq(G) CC CG GG
/ 186 282 111 43.5% 190 296 133 45.4% 1 1.12 (.97–1.29) 1.25 (.94–1.67)
/ 33 39 22 44.1% 59 123 69 52.0% 2.47 (1.90–3.22) 2.77 (2.06–3.71) 3.10 (2.12–4.53)
/ 0 2 1 … 11 41 21 56.8% 22.05 (7.30–66.67) 24.70 (8.13–75.06) 27.67 (8.89–86.04)
NOTE.—CARD15 genotypes are defined by the presence or absence of three CD DSAs: / (wild type), / (heterozygous for mutation),
and / (homozygous or compound heterozygous for mutation).
a N p number of case and control subjects.
genotyped in 267 unrelated individuals and confirmed to
be in strong LD ( ; ). C2063G, which′Dp 0.87 D p 0.91
is a nonsynonymous change in a GENSCAN predicted
gene (Rioux et al. 2001), was then genotyped in a set of
427 British and 138 German families (Hampe et al. 1999)
containing a total of 511 offspring with CD and 320 with
UC. All genotyping was performed using the TaqMan
biallelic discrimination system (Livak et al. 1995) on an
ABI 7700 DNA analyzer. Allelic transmission distortion
to these two disease phenotypes was assessed by the trans-
mission-disequilibrium test (TDT) (Spielman et al. 1993),
implemented using TRANSMIT (Clayton 1999). An as-
sociation test using transmission to all affected offspring
was performed by a bootstrap simulation across families
(TRANSMIT). A x2 test confirmed that genotypes were
in Hardy-Weinberg equilibrium. Excess transmission of
the G allele of the C2063G SNP to affected offspring was
observed in CD ( (table 1) but not in UC. ThePp .016
SNP was then genotyped in an independent set of un-
related British individuals with CD ) and UC(np 684
( ) (Cuthbert et al. 2002) and in 701 British con-np 388
trol subjects. The frequency of the G allele in patients
with CD was significantly higher than in controls (Pp
) but was not increased in patients with UC (table.008
1). The CD odds ratios (ORs) for the CG and GG geno-
types were 1.19 (95% CI 0.93–1.52) and 1.49 (95% CI
1.11–2.01), respectively.
In view of the strong contribution of mutations in the
CARD15 gene to the risk of CD, we investigated the
possibility of interaction between this gene and the 5q31
locus in CD. Both the TDT and the case-control sample
were genotyped for the C2063G SNP and for the three
SNPs in theCARD15 gene (R702W, G908R, and 1007fs)
that are independently associatedwith disease risk (Hugot
et al. 2001; Cuthbert et al. 2002). In the TDT sample,
stratification of offspring with CD by theirCARD15mu-
tation status showed some evidence of association in off-
spring carrying at least one CARD15 disease-susceptibil-
ity allele (DSA) ( ; ) but no associationnp 203 Pp .044
in offspring without the three mutations ( ;np 259
). No significant differences in the distribution ofPp .20
CARD15 and 5q31 genotypes were observed between
familial and sporadically ascertained patients with CD
( ). A single individual with CD was therefore ran-Pp .7
domly selected from each family, and thesewere combined
with the sporadically ascertained patients with CD, pro-
viding a total of 943 unrelated patients with CD and 676
control subjects. These patients with CD and control sub-
jects were stratified according to whether they had no,
one, or two CARD15 DSAs, and the frequency of the
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Figure 1 Kaplan-Meyer survival curves (age until disease onset) for the baseline genotype A/ (2063 CC/CG, no CARD15 DSAs) and
CARD15/5q31 early-onset risk genotypes: A/ (2063 CC/CG, one or two CARD15 DSAs), A/ (2063 GG, no CARD15 DSAs) and A/
(2063 GG, one or two CARD15 DSAs).
C2063G SNP was determined in these three groups (table
2). By use of a x2 test of independence of ordinal data,
the distribution of C2063G genotypes was shown to be
associated with the number of CARD15 mutations in
patients with CD ( ) but not in control subjectsPp .001
( ). Individuals with CD who had one or twoP 1 .5
CARD15 DSAs had a significantly higher frequency of
the 2063G allele than those with none (53.1% vs. 45.4%;
). The frequency of 2063G in all unrelated in-Pp .0018
dividuals with CD (48.0%) was significantly higher than
in control subjects (43.7%; ). The associationPp .016
of this haplotype with CD was much stronger in affected
individuals with one or two CARD15 DSAs (53.1% vs.
43.7% in control subjects; ) but was not sig-Pp .0001
nificant in case subjects with CD who had no CARD15
DSAs (45.4% vs. 43.7%; ). There was no sig-Pp .41
nificant difference in G allele frequency in control subjects
with different CARD15 genotypes. Logistic regression
analysis by Splus v5.1 was then used to estimate ORs for
each genotype and for combinations of genotypes, mod-
eling case/control status on 5q31 andCARD15 genotypes
(table 2). Risk owing to 5q31 wasmodeled by the number
of alleles (zero, one, or two), and independent risks were
calculated for CARD15 genotypes, giving an OR of 1.12
for each copy of the 5q31 G allele and ORs of 2.47 and
22.05 for CARD15 / and /, respectively. ORs for
specific 5q31/CARD15 genotypes were obtained by mul-
tiplying the baseline contributions for each locus, and
95% CIs were obtained directly from logistic regression
parameter estimates. CARD15 contributed most of the
disease risk ); the increased risk owing to 5q3110(P ! 10
genotypes in individuals with CD carrying no CARD15
DSAs was not significant. The combined population at-
tributable risk for these two loci was 31%.
The strongest evidence for linkage to 5q31 has been
found in families with early-onset CD (Rioux et al. 2000).
We therefore considered the effects ofCARD15 and 5q31
loci on age at disease onset in 500 independent individ-
uals with CD. Survival curves (years until age at CD
onset) were calculated using Kaplan-Meier survival anal-
ysis (Splus v5.1) and were compared using a Mantel-
Haenszel test (fig. 1). A significantly earlier age at onset
occurred in the 2063 GG patients with CD than in CC/
CG patients with CD ( ); an earlier age at onsetPp .0019
in patients with CD carrying at least one CARD15 DSA
wasmarginally significant ( ). The age at diseasePp .048
onset in patients with CD with the genotype A/ (2063
CC/CG, no CARD15 DSAs) was therefore compared
with each of the two-locus early-onset high-risk geno-
types, A/ (CC/CG, at least one CARD15 DSA), A/
(GG, no CARD15 DSAs), and A/ (GG, at least one
CARD15 DSA) (table 3). A significantly earlier age at
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Table 3
Disease Onset Age Distribution by CARD15/5q31 Genotypes and
Comparison of Baseline and Risk Genotypes
DISEASE ONSET
RISK GENOTYPE
AGE AT ONSET
(YEARS) NO. OF CASES
Mean Median (95% CI)
Observed
(N) Expecteda (Pb)
A/ 30.1 27 (25–29) 244 …
A/ 27.1 23 (20–26) 121 105.0 (.058)
A/ 25.2 23 (22–25) 73 52.9 (.002)
A/ 24.1 21 (19–24) 43 28.6 (.003)
a Expected number of cases, under the assumption of no difference in age at
disease onset between risk genotype (2063 GG or one or two CARD15 DSAs)
and baseline genotype (no or one copy of 2063 G allele and noCARD15DSAs).
b P value obtained from test of difference between two survival curves (risk
genotype vs. baseline genotype).
onset occurred in both 2063 GG patients with CD who
also carried at least one CARD15 DSA (A/; median
age 21 years; ) and those who did not carry aPp .003
CARD15 DSA (A/; median age 23 years; ),Pp .002
compared with the baseline genotype (A/; median age
27 years). The age at onset in 2063 GG patients with
CD who also carried at least one CARD15 DSA (A/)
was not significantly different from those without a
CARD15 DSA. In 2063 CC/CG patients with CD, the
effect of CARD15 on age at onset was only marginally
significant ( ). Disease-onset risk ratios, as de-Pp .058
fined by the ratio of the relative disease-onset rates (ob-
served/expected number of cases) for the risk and base-
line genotypes (table 3), were calculated. The relative
disease onset risk ratios between two-locus risk geno-
types and the baseline genotype are 1.23 (A/), 1.49
(A/), and 1.59 (A/). By age 21 years, 58.1% of 2063
GG patients with CD who also carried at least one
CARD15 DSA had developed the disease (95% CI
40.5–70.6) compared with 27.5% of patients with CD
who did not carry a 5q31 or CARD15 risk genotype
(95% CI 21.6–32.9). By age 36 years, 93% of individ-
uals with the high-risk genotype at both loci had de-
veloped the disease. We have shown elsewhere that the
presence of CARD15mutations was associated with the
ileal form of CD (Cuthbert et al. 2002). We therefore
investigated the possibility of an association of the 5q31
haplotype with the site of disease in 551 independent
individuals with CD. No association was found; the fre-
quency of the 2063G allele was 48.7% in affected in-
dividuals with ileal disease and 48.4% in affected in-
dividuals with colon-specific disease ( ).Pp .99
Our family- and population-based tests for association
of genetic variation at the cytokine gene cluster on chro-
mosome 5q31 and disease support the primary evidence
for the existence of a CD susceptibility gene at this locus
(IBD5) (Rioux et al. 2001). We found no evidence of
association with UC, which was not tested in the original
study. The disease risk conferred by this locus in our large
sample of individuals with CD was only 1.49 in 2063G
homozygotes, which is substantially less than the sixfold
risk predicted by Rioux et al (2001). The low risk is con-
sistent with the absence of significant linkage to this locus
in the genome scan from the British and German popu-
lations (Hampe et al. 1999) and underlines the difficulty
in detection of linkage at loci of modest effect (Risch and
Merikangas 1996). The most striking properties of the
5q31 locus, however, were its significantly higher fre-
quency in our sample of 943 patients with CD who had
one or two CARD15 mutations and its association with
a younger age at disease onset. The early onset is consis-
tent with the original linkage study (Rioux et al. 2000),
which showed a higher LOD score at this locus in families
with at least one affected sibling with a diagnosis at age
16 years or younger. These authors did not find evidence
of interaction of the 5q31 disease risk haplotype with
CARD15 in 84 CD trios but pointed out that larger sam-
ples might be required to detect it (Vermeire et al. 2002).
The identity of the actual disease susceptibility gene at
the 5q31 locus is unknown, but our findings suggest that
it may interact with CARD15 in a common pathophy-
siological pathway. The 5q31 locus contains the genes for
the cytokines IL4, IL5, and IL13, and CARD15 appears
to be involved in bacterial lipopolysaccharide-induced ac-
tivation of the transcription factor NF-kB inmononuclear
phagocytes (Ogura et al. 2001). Since abnormal regula-
tion of monocyte activation by IL4 and IL13 has been
described in CD (Schreiber et al. 1995), it is possible that
a hypomorphic allele in one of these regulatory cytokines
in combination with a mutation in CARD15may lead to
an early and persistent proinflammatory response in the
gastrointestinal tract. Thus, the 5q31 locus may contain
a modifier gene which hastens disease onset in some ge-
netically susceptible individuals. Suchmodelsmust remain
speculative until the function of CARD15 is more pre-
cisely defined and the identity of the CD susceptibility
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gene at 5q31 is known. These loci have roles in other
inflammatory disorders; genetic and functional studies
have implicated the 5q31 cytokine gene cluster in asthma
(Cookson 2002), and mutations in CARD15 have been
detected in Blau syndrome, which is aMendelian disorder
characterized by granulomatous arthritis (Miceli-Richard
et al. 2001). The connection between these two loci in
CD may, therefore, be of broader significance in the eti-
ology of chronic inflammatory disease.
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